ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

ACADIA Pharmaceuticals ( ACAD) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.5%. By the end of trading, ACADIA Pharmaceuticals fell $0.87 (-3.3%) to $25.44 on light volume. Throughout the day, 1,145,401 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 2,445,600 shares. The stock ranged in price between $25.40-$26.50 after having opened the day at $26.30 as compared to the previous trading day's close of $26.31. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 39.1%, Oramed Pharmaceuticals ( ORMP), down 21.3%, Heat Biologics ( HTBX), down 7.4% and Hemispherx Biopharma ( HEB), down 6.4%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $2.4 billion and is part of the drugs industry. Shares are up 465.8% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Coronado Biosciences ( CNDO), up 26.7%, Inovio Pharmaceuticals ( INO), up 20.2%, Apricus Biosciences ( APRI), up 16.6% and Amyris ( AMRS), up 15.3% , were all gainers within the health care sector with Allergan ( AGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon